Statin and non-steroidal anti-inflammatory drug use in relation to clinical outcome among patients with Rai stage 0 chronic lymphocytic leukemia

References

• Kaufman DW, Kelly JP, Rosenberg L, Anderson TE, Mitchell AA. Recent patterns of medication use in the ambulatory adult population of the United States: the Slone survey. JAMA 2002;287:337–344.
   PubMed Web of Science ®Google Scholar
• Mann D, Reynolds K, Smith D, Muntner P. Trends in statin use and low-density lipoprotein cholesterol levels among US adults: impact of the 2001 National Cholesterol Education Program guidelines. Ann Pharmacother 2008;42:1208–1215.
   PubMed Web of Science ®Google Scholar
• Solomon D. Nonselective NSAIDs: overview of adverse effects. 2009. Available from: http://www.uptodate.com.
   Google Scholar
• Endo A. The discovery and development of HMG-CoA reductase inhibitors. 1992. Atheroscler Suppl 2004;5:67–80.
   PubMed Web of Science ®Google Scholar
• Jakobisiak M, Golab J. Potential antitumor effects of statins (Review). Int J Oncol 2003;23:1055–1069.
   PubMed Web of Science ®Google Scholar
• Zhuang L, Kim J, Adam RM, Solomon KR, Freeman MR. Cholesterol targeting alters lipid raft composition and cell survival in prostate cancer cells and xenografts. J Clin Invest 2005;115:959–968.
   PubMed Web of Science ®Google Scholar
• Perez-Sala D, Mollinedo F. Inhibition of isoprenoid biosynthesis induces apoptosis in human promyelocytic HL-60 cells. Biochem Biophys Res Commun 1994;199:1209–1215.
   PubMed Web of Science ®Google Scholar
• Mausner-Fainberg K, Luboshits G, Mor A, et al The effect of HMG-CoA reductase inhibitors on naturally occurring CD4+CD25+ T cells. Atherosclerosis 2008;197:829–839.
   PubMed Web of Science ®Google Scholar
• Schramm R, Menger MD, Harder Y, et al Statins inhibit lymphocyte homing to peripheral lymph nodes. Immunology 2007;120:315–324.
   PubMed Web of Science ®Google Scholar
• Chapman-Shimshoni D, Yuklea M, Radnay J, Shapiro H, Lishner M. Simvastatin induces apoptosis of B-CLL cells by activation of mitochondrial caspase 9. Exp Hematol 2003;31:779–783.
   PubMed Web of Science ®Google Scholar
• Vitols S, Angelin B, Juliusson G. Simvastatin impairs mitogen-induced proliferation of malignant B-lymphocytes from humans–in vitro and in vivo studies. Lipids 1997;32:255–262.
   PubMed Web of Science ®Google Scholar
• Madden EA, Melnykovych G, Fiskin AM. Compactin (ML-236B) reduces the content of filipin-cholesterol complexes in the plasma membrane of chronic lymphocytic leukemia cells. Exp Cell Res 1984;153:91–98.
   PubMed Web of Science ®Google Scholar
• Weinberg JB, Volkheimer AD, Mihovilovic M, et al Apolipoprotein E genotype as a determinant of survival in chronic lymphocytic leukemia. Leukemia 2008;22:2184–2192.
   PubMed Web of Science ®Google Scholar
• Oppezzo P, Vasconcelos Y, Settegrana C, et al The LPL/ADAM29 expression ratio is a novel prognosis indicator in chronic lymphocytic leukemia. Blood 2005;106:650–657.
   PubMed Web of Science ®Google Scholar
• Nuckel H, Huttmann A, Klein-Hitpass L, et al Lipoprotein lipase expression is a novel prognostic factor in B-cell chronic lymphocytic leukemia. Leuk Lymphoma 2006;47:1053–1061.
   PubMed Web of Science ®Google Scholar
• Heintel D, Kienle D, Shehata M, et al High expression of lipoprotein lipase in poor risk B-cell chronic lymphocytic leukemia. Leukemia 2005;19:1216–1223.
   PubMed Web of Science ®Google Scholar
• Elwood PC, Gallagher AM, Duthie GG, Mur LA, Morgan G. Aspirin, salicylates, and cancer. Lancet 2009;373:1301–1309.
   PubMed Web of Science ®Google Scholar
• Ryan EP, Pollock SJ, Kaur K, et al Constitutive and activation-inducible cyclooxygenase-2 expression enhances survival of chronic lymphocytic leukemia B cells. Clin Immunol 2006;120:76–90.
   PubMed Web of Science ®Google Scholar
• Bellosillo B, Pique M, Barragan M, et al Aspirin and salicylate induce apoptosis and activation of caspases in B-cell chronic lymphocytic leukemia cells. Blood 1998;92:1406–1414.
   PubMed Web of Science ®Google Scholar
• Ryan EP, Bushnell TP, Friedman AE, Rahman I, Phipps RP. Cyclooxygenase-2 independent effects of cyclooxygenase-2 inhibitors on oxidative stress and intracellular glutathione content in normal and malignant human B-cells. Cancer Immunol Immunother 2008;57:347–358.
   PubMed Web of Science ®Google Scholar
• Robak P, Linke A, Cebula B, Robak T, Smolewski P. Cytotoxic effect of R-etodolac (SDX-101) in combination with purine analogs or monoclonal antibodies on ex vivo B-cell chronic lymphocytic leukemia cells. Leuk Lymphoma 2006;47:2625–2634.
   PubMed Web of Science ®Google Scholar
• Lindhagen E, Nissle S, Leoni L, et al R-etodolac (SDX-101) and the related indole-pyran analogues SDX-308 and SDX-309 potentiate the antileukemic activity of standard cytotoxic agents in primary chronic lymphocytic leukaemia cells. Cancer Chemother Pharmacol 2007;60:545–553.
   PubMed Web of Science ®Google Scholar
• Winiarska M, Bil J, Wilczek E, et al Statins impair antitumor effects of rituximab by inducing conformational changes of CD20. PLoS Med 2008;5:e64.
   PubMed Web of Science ®Google Scholar
• Hallek M. Immunochemotherapy with fludarabine (F), cyclophosphamide (C), and rituximab (R) (FCR) versus fludarabine and cyclophosphamide (FC) improves response rates and progression-free survival (PFS) of previously untreated patients (pts) with advanced chronic lymphocytic leukemia (CLL). Blood 2008;112(Suppl. 1): (Abstract 325).
   Google Scholar
• Hallek M, Fingerle-Rowson G, Fink A, et al First-line treatment with fludarabine (F), cyclophosphamide (C), and rituixmab (R) (FCR) improves overall survival (OS) in previously untreated patients (pts) with advanced chronic lymphocytic leukemia (CLL): results of a randomized phase III trial on behalf of an international group of investigators and the German CLL Study Group. Blood 2009;114(Suppl. 1): (Abstract 535).
   Google Scholar
• Robak T, Moiseev SI, Dmoszynska A, et al Rituximab, fludarabine, and cyclophosphamide (R-FC) prolongs progression free survival in relapsed or refractory chronic lymphocytic leukemia (CLL) compared with FC alone: final results from the international randomized phase III REACH Trial. Blood 2008;112(Suppl. 1): (Abstract 1).
   Google Scholar
• Rabinowitz I. Interaction between statins and rituximab in non-Hodgkin's lymphoma. J Clin Oncol 2008;26: 5486; author reply 5486.
   PubMed Web of Science ®Google Scholar
• Goldstein MR, Mascitelli L, Pezzetta F. Monoclonal antibody therapy and non-Hodgkin's lymphoma. N Engl J Med 2009;360:192; author reply 193.
   PubMed Web of Science ®Google Scholar
• Nowakowski GS, Maurer MJ, Habermann TM, et al Statin use and prognosis in patients with diffuse large B-cell lymphoma and follicular lymphoma in the rituximab era. J Clin Oncol 2010;28:412–417.
   PubMed Web of Science ®Google Scholar
• Shanafelt TD, Jelinek D, Tschumper R, et al Cytogenetic abnormalities can change during the course of the disease process in chronic lymphocytic leukemia. J Clin Oncol 2006;24:3218–3219.
   PubMed Web of Science ®Google Scholar
• Zent CS, Ding W, Schwager SM, et al The prognostic significance of cytopenia in chronic lymphocytic leukaemia/small lymphocytic lymphoma. Br J Haematol 2008;141:615–621.
   PubMed Web of Science ®Google Scholar
• Maddocks-Christianson K, Slager SL, Zent CS, et al Risk factors for development of a second lymphoid malignancy in patients with chronic lymphocytic leukaemia. Br J Haematol 2007;139:398–404.
   PubMed Web of Science ®Google Scholar
• Thurmes P, Call T, Slager S, et al Comorbid conditions and survival in unselected, newly diagnosed patients with chronic lymphocytic leukemia. Leuk Lymphoma 2008;49:49–56.
   PubMed Web of Science ®Google Scholar
• Bowen DA, Call TG, Jenkins GD, et al Methylprednisolone-rituximab is an effective salvage therapy for patients with relapsed chronic lymphocytic leukemia including those with unfavorable cytogenetic features. Leuk Lymphoma 2007;48:2412–2417.
   PubMed Web of Science ®Google Scholar
• Palmer S, Hanson CA, Zent CS, et al Prognostic importance of T and NK-cells in a consecutive series of newly diagnosed patients with chronic lymphocytic leukaemia. Br J Haematol 2008;141:607–614.
   PubMed Web of Science ®Google Scholar
• Dewald G, Brockman S, Paternoster S, et al Chromosome anomalies detected by interphase fluorescence in situ hybridization: correlation with significant biological features of chronic lymphocytic leukemia. Br J Haematol 2003;121:287–295.
   PubMed Web of Science ®Google Scholar
• Jelinek DF, Tschumper RC, Geyer SM, et al Analysis of clonal B-cell CD38 and immunoglobulin variable region sequence status in relation to clinical outcome for B-chronic lymphocytic leukaemia. Br J Haematol 2001;115:854–861.
   PubMed Web of Science ®Google Scholar
• Shanafelt TD, Witzig TE, Fink SR, et al Prospective evaluation of clonal evolution during long-term follow-up of patients with untreated early-stage chronic lymphocytic leukemia. J Clin Oncol 2006;24:4634–4641.
   PubMed Web of Science ®Google Scholar
• Friedman DR, Harrison JD, Magura LA, Warren HA, Diehl LF, Weinberg JB. Influence of statin therapy on the clinical course of chronic lymphocytic leukemia. Blood 2009;114(Suppl. 1): (Abstract 2344).
   PubMed Web of Science ®Google Scholar
• Jensen M, Engert A, Weissinger F, et al Phase I study of a novel pro-apoptotic drug R-etodolac in patients with B-cell chronic lymphocytic leukemia. Invest New Drugs 2008;26:139–149.
   PubMed Web of Science ®Google Scholar
• Moon EY, Lerner A. Benzylamide sulindac analogues induce changes in cell shape, loss of microtubules and G(2)-M arrest in a chronic lymphocytic leukemia (CLL) cell line and apoptosis in primary CLL cells. Cancer Res 2002;62:5711–5719.
   PubMed Web of Science ®Google Scholar